Venomics AI Raises $2.7M to Turn Animal Venom Into Life-Saving Medicines Using AI

Venomics AI Secures $2.7 Million to Advance Venom-Based Drug Discovery

Venomics AI has raised $2.7 million in a pre-seed funding round co-led by Speciale Invest and South Park Commons, with participation from Operators Studio1

1

. The Bengaluru-based biotechnology startup, spun out of the Indian Institute of Science, is building an AI-driven platform for drug discovery that combines venom biology and artificial intelligence to identify and develop venom-derived molecules into therapeutic leads2

2

.

Expanding the Venom Atlas and AI Capabilities

The fresh capital will support the expansion of Venom Atlas, the company's growing molecular dataset of venom-derived compounds, and strengthen its AI and laboratory screening capabilities1

1

. Venomics AI plans to expand its multidisciplinary team across venom biology, computational science and drug discovery, while supporting the validation and optimisation of promising molecules2

2

. The platform combines molecular sequencing and venom biology to map molecular diversity, uses AI to prioritise promising candidates, and validates predictions through functional laboratory screening1

1

.

Tapping Nature's Unexplored Molecular Diversity

Animal venoms contain complex molecules that have evolved over millions of years to interact with specific biological targets. Some of these compounds have already inspired medicines like captopril, inspired by snake venom peptides, and ziconotide, derived from a cone snail venom peptide2

2

. However, much of the molecular diversity across venomous species remains unexplored, presenting a significant opportunity for venom-based medicine development1

1

.

Founders Bring Deep Expertise in Venom Biology and AI

Venomics AI was co-founded by Kartik Sunagar and Vinay Prabhu, bringing together expertise in venom biology and artificial intelligence2

2

. Sunagar, a Professor at IISc, stated that animal venoms represent one of nature's richest yet least explored sources of potential medicines, and the company is combining cutting-edge experimental science with artificial intelligence to unlock this extraordinary potential1

1

. Prabhu, Chief Technology Officer, holds a PhD from Carnegie Mellon University and brings expertise in machine learning and large-scale AI systems2

2

.

India's Biotech Sector Sees Growing Investment

India's bioeconomy is on track to reach $300 billion by 2030, with the country emerging as a global biotechnology hub1

1

. The biotech sector has been booming, with India now home to more than 11,000 biotech startups1

1

. Finance minister Nirmala Sitharaman announced a new Biopharma SHAKTI scheme with an outlay of ₹10,000 crore as part of Budget 20271

1

. Investor interest has been growing, with Cellogen Therapeutics securing ₹20 crore in funding from Kotak Alternate Asset Managers and StrainX Bioworks raising $13 million in a funding round led by Prime Venture Partners and Leo Capital1

1

.

Leveraging India's Biodiversity Advantage

Arjun Rao, General Partner at Speciale Invest, noted that India's venom biodiversity is among the richest in the world, and Sunagar is one of the world's leading experts on it2

2

. The combination of deep understanding of venoms with access to study them, paired with AI depth, positions the company to build the Venom Atlas as a unique dataset that will power AI to find drugs for some of the world's most pressing diseases2

2

. The company has established the initial architecture of its platform, joined the NVIDIA Inception programme, and been selected among the Top 5 finalists for the 2026 Indo-Boston Biotech Bridge Award2

2

.